BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.50 Average Price Target from Analysts

On February 20, 2025, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gained attention from analysts as it received an average recommendation of "Moderate Buy". Currently, six brokerages are covering the stock. Among these analysts, one has given the stock a hold rating, while five have issued buy ratings. The average price target set for the next twelve months among those brokerages stands at $15.50.

Various analyst reports have discussed BCRX. For instance, Barclays recently raised their price target for BioCryst Pharmaceuticals from $7.00 to $8.00, advising an "equal weight" rating on the stock in a report dated November 5. Meanwhile, Evercore ISI improved their target price from $10.00 to $12.00, assigning a rating of "outperform" on January 13. Additionally, Needham & Company LLC increased their target from $14.00 to $15.00 and maintained a "buy" rating on the stock in the same January report. Royal Bank of Canada re-iterated its "outperform" rating and set the price target at $10.00 in November. Lastly, JMP Securities assigned an "outperform" rating with a more ambitious target of $18.00 in their report on January 31.

Institutional Investment Insights

Hedge funds have also shown interest in BioCryst Pharmaceuticals recently. In the fourth quarter, GF Fund Management CO. LTD. added a new stake valued at approximately $33,000, while Venturi Wealth Management LLC acquired a stake worth around $46,000. R Squared Ltd also entered into a new position with shares valued at about $48,000. Furthermore, Mirae Asset Global Investments Co. Ltd. increased its holdings by 21.5% in the third quarter, bringing their total ownership to 7,483 shares, worth approximately $57,000. KBC Group NV boosted its stake by an impressive 80.1%, owning 10,198 shares valued at about $77,000 after making recent acquisitions. Overall, institutional and hedge fund investors hold 85.88% of the company’s stock.

Current Stock Performance

As of the latest trading session, shares of BioCryst Pharmaceuticals opened at $9.39. The stock has witnessed significant movement lately, with a 50-day moving average of $7.94 and a 200-day moving average of $7.81. The biotechnology company enjoys a market capitalization of $1.94 billion with a price-to-earnings ratio of -15.39 and a beta of 1.75. Over the past year, the stock has seen a low of $4.03 and a high of $9.48, indicating notable volatility and growth potential.

Company Overview

BioCryst Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing oral small-molecule drugs and protein therapeutics aimed at treating rare diseases. The company's portfolio includes peramivir injection, which is an intravenous neuraminidase inhibitor used for treating acute uncomplicated influenza, marketed under the names RAPIVAB, RAPIACTA, and PERAMIFLU. Additionally, the company offers ORLADEYO, an oral serine protease inhibitor that treats hereditary angioedema.

BioCryst, Pharmaceuticals, Analysts